GraceFinance · Source-backed public company research
Genenta Science S.p.A. (GNTA)
Nasdaq · Manufacturing · Biological Products, (No Diagnostic Substances)
Core research established · 4/4 core data layers currently established
What Genenta Science S.p.A. does
A. History and Development of the Company Corporate History and Operating Segment Evolution We were founded in 2014 by San Raffaele Hospital (Ospedale San Raffaele or “OSR”) in Milan, a globally recognized premier research hospital for ex-vivo gene therapy, with Pierluigi Paracchi (our CEO), Prof. Luigi Naldini, and Dr. Bernhard Gentner, to develop potential ground-breaking cell and gene cancer therapies. We leverage the vast experience in lentiviral vector (“LVV”) technology of the San Raffaele Telethon Institute for Gene Therapy (“SR-Tiget”). SR-Tiget, a joint venture between OSR and Fondazione Telethon (“Telethon”), is a world-leading cell and gene therapy research institution at the forefront of developing therapies for rare diseases.
Open the company story
The live GraceFinance page shows source-backed financial changes, management context, guidance, confirmed events, risks, and connected history only when the applicable evidence and relationships have been established. Missing research stays visible instead of being inferred.